Please login to the form below

Not currently logged in
Email:
Password:

Inflectra

This page shows the latest Inflectra news and features for those working in and with pharma, biotech and healthcare.

Merck & Co's Remicade biosimilar undercuts its US rivals

Merck & Co's Remicade biosimilar undercuts its US rivals

Pfizer and Celltrion's Inflectra (infliximab-dyyb) biosimilar was priced at a 15% discount to Remicade's $30, 000-a-year price tag. ... Sales were flat in 2016 as a whole - Inflectra did not launch until the fourth quarter - but fell 6% in the first

Latest news

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    competition from Pfizer's Inflectra, Mundipharma's Remsima and Samsung Bioepis' Renflexis/Flixabi. ... Currently only Inflectra is available in the US market - which accounts for two thirds of Remicade sales - but Samsung's biosimilar is expected to be

  • Standing out in a crowd Standing out in a crowd

    Last year it won the first European and US approvals for a biosimilar version of the blockbuster arthritis treatment Remicade (infliximab), which is marketed under the brand names Remsima and Inflectra. ... patients that could have been switched from

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    If approved, the epoetin alfa biosimilar would be Pfizer's second in the US, after it got the go-ahead from the FDA to sell Inflectra (infliximab-dyyb), a biosimilar of

  • Pfizer’s Remicade biosimilar receives Crohn's trial boost Pfizer’s Remicade biosimilar receives Crohn's trial boost

    Inflectra shown to be similar to originator in data presented at ECCO in Barcelona.  . ... In it Inflectra met its primary end point by demonstrating at six-weeks it was similar to Remicade.

  • J&J pondering future of diabetes device assets J&J pondering future of diabetes device assets

    by the recent launch of a biosimilar competitor - Pfizer's Inflectra - in the US at a 15% discount to the brand.

More from news
Approximately 7 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    Pfizer also cited a Janssen brochure that allegedly implied the biosimilar Inflectra is not interchangeable with Remicade and may pose a safety risk.

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima. ... Meanwhile, as Europe focuses on the market debuts of

  • Pharma deals in February 2015 Pharma deals in February 2015

    zeta) and Nivestim (filgrastim), and the Remicade copycat  Inflectra (infliximab), the first monoclonal antibody to be approved.

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    The recent approval of Hospira's Inflectra (infliximab) may mark a turning point for biosimilars in Europe. ... products in development (see chart overleaf), with Remsima/Inflectra the only biosimilar mentioned specifically by name. .

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Infographic: RA Perceptions

    Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...

Infographics